布预测阿尔茨海默氏症痴呆症的进展速度更快
Audrey A Keleman1,2,3, Melody Li4, Julie K Wisch4
1Program in Occupational Therapy, Washington University School of Medicine, St. Louis, Missouri, USA.
Alzheimer's & dementia : the journal of the Alzheimer's Association
|February 7, 2026
概括
在没有认知障碍的老年人中,跌倒可能表明阿尔茨海默病 (AD) 的进展速度更快. 患有临床前阿尔茨海默氏症和跌倒的个体最快地发展为轻度痴呆症.
科学领域:
- 神经科学是一个神经科学.
- 老年学是一门学科.
- 神经学 神经学
背景情况:
- 临床前阿尔茨海默氏症 (AD) 在认知正常的个体中涉及大脑粉样蛋白的积累 (临床痴呆症评分 [CDR] = 0).
- 区分健康的衰老和临床前AD是很困难的,因为重叠的与年龄相关的损伤,如跌倒.
- 跌倒在老年人中很常见,可以是神经系统变化的早期指标.
研究的目的:
- 研究患有临床前阿尔茨海默氏症的个体中跌倒和认知衰退之间的关联.
- 为了确定跌倒是否会加速从临床前AD向轻度痴呆症的进展 (CDR 1).
主要方法:
- 一项纵向队列研究追踪了125名认知正常 (CDR 0) 的老年人,平均为10年.
- 病例被监测了一年,并在基线评估了临床前AD状态 (粉样蛋白).
- 参与者根据临床前AD状态和跌倒发生情况分为四组:临床前AD-Fall,临床前AD-Fall+,临床前AD+Fall和临床前AD+Fall+.
- 使用生存分析,在不同组中比较时间到CDR 1 (轻度痴呆症) 的进展.
主要成果:
- 临床前AD+Fall+组显示 CDR 1 的进展最快.
- 没有临床前AD和没有跌倒的个体 (临床前AD-跌倒) 呈现出最慢的进展.
- 患有临床前AD但没有跌倒的人 (临床前AD+跌倒) 和没有临床前AD但有跌倒的人 (临床前AD-跌倒+) 的进展率相似.
结论:
- 跌倒可能是加速阿尔茨海默氏症痴呆症进展的早期指标.
- 该协会认为,跌倒可能反映了与AD病理学相关的潜在运动和步行功能障碍.
- 识别认知能力正常的个体的跌倒风险可能有助于早期检测AD进展.
相关概念视频
01:26Psychosis: Goals of Pharmacotherapy
706
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
706
01:26Alzheimer's Disease: Overview
1.7K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.7K
01:22Alzheimer's Disease: Treatment
1.3K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K
01:29Alzheimer Disease l: Introduction
21
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
21
01:23Alzheimer Disease ll: Pathophysiology
35
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and...
35
01:21Huntington Disease l: Introduction
110
Huntington disease or HD is a progressive, fatal neurodegenerative disorder inherited in an autosomal dominant pattern.PathophysiologyIt is caused by expansion of the CAG trinucleotide repeat in the HTT gene on chromosome 4 (4p16.3), producing an abnormal huntingtin protein with an expanded polyglutamine tract. This misfolded protein disrupts cellular function, leading to neuronal death. Normal alleles have ≤26 repeats, 27–35 are intermediate (risk of expansion), 36–39 show...
110